|
122 Companies |
|
161 Products |
|
161 Products |
|
115 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| 12345678910111213...4950» |
- | Enrollment change: Anti-HIV Medications for People Recently Infected With HIV (clinicaltrials.gov) - Sep 13, 2023
P4, N=113, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
N=180 --> 113
- | Enrollment change: TBTech: Clinical Decision-support Reminders to Improve IPT Initiation Among HIV Positive Adults in Western Kenya (clinicaltrials.gov) - Mar 27, 2023
P=N/A, N=3782, Completed, Sponsor: Indiana University
N=180 --> 113 N=1000 --> 3782
- | Trial completion, Enrollment change: INTESTIPAX: IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection (clinicaltrials.gov) - Apr 30, 2019
P=N/A, N=26, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=1000 --> 3782 Recruiting --> Completed | N=45 --> 26
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change: Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy (clinicaltrials.gov) - Apr 23, 2019
P1/2, N=7, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=45 --> 26 N=25 --> 7
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change, Metastases: A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter na (clinicaltrials.gov) - Apr 23, 2019
P3, N=47, Completed, Sponsor: University of Modena and Reggio Emilia
N=25 --> 7 Recruiting --> Completed | N=350 --> 47
- | Trial completion date, Trial termination, Trial primary completion date: Viral and Host Factors in the Transmission and Pathogenesis of HIV (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=600, Terminated, Sponsor: Rockefeller University
Trial completion date: Jul 2019 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Mar 2019; Blood drawing protocol for RUH/ADARC. ADARC ceasing operations at RUH
- | Trial completion, Trial completion date: Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis (clinicaltrials.gov) - Apr 20, 2019
P3, N=331, Completed, Sponsor: Tuberculosis Research Centre, India
ADARC ceasing operations at RUH Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018
- | Trial completion, Enrollment change: Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=40, Completed, Sponsor: Albert Einstein College of Medicine
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 Recruiting --> Completed | N=100 --> 40
- | amphotericin b liposome / Generic mfg.
Trial completion, Enrollment change, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Apr 20, 2019
P3, N=59, Completed, Sponsor: Drugs for Neglected Diseases
Recruiting --> Completed | N=100 --> 40 Active, not recruiting --> Completed | N=132 --> 59
- || THV-01 / TheraVectys
Trial completion: Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - Apr 19, 2019
P1/2, N=38, Completed, Sponsor: Theravectys S.A.
Active, not recruiting --> Completed | N=132 --> 59 Active, not recruiting --> Completed
- | Phase classification: Fish Oil for HIV-Related Inflamm-aging and Immune Senescence (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=37, Completed, Sponsor: Rush University Medical Center
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- | Isentress (raltegravir) / Merck (MSD)
Trial termination: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Apr 19, 2019
P2, N=11, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P=N/A Completed --> Terminated; This study was terminated early due to poor recruitment.
- | ibandronate sodium hydrate / Generic mfg.
Enrollment change, Trial withdrawal: Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort (clinicaltrials.gov) - Mar 13, 2019
P4, N=0, Withdrawn, Sponsor: Germans Trias i Pujol Hospital
Completed --> Terminated; This study was terminated early due to poor recruitment. N=65 --> 0 | Suspended --> Withdrawn
- | Trial completion, Phase classification, Enrollment change: Computerized Cognitive Rehabilitation in Ugandan Children With HIV (clinicaltrials.gov) - Mar 6, 2019
P=N/A, N=159, Completed, Sponsor: Michigan State University
N=65 --> 0 | Suspended --> Withdrawn Suspended --> Completed | Phase classification: P1 --> PN/A | N=60 --> 159
- | trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) (clinicaltrials.gov) - Mar 5, 2019
P3, N=200, Completed, Sponsor: University of California, San Francisco
Suspended --> Completed | Phase classification: P1 --> PN/A | N=60 --> 159 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2016 | Trial primary completion date: Aug 2018 --> May 2016
- | Trial completion, Trial completion date, Trial primary completion date: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Feb 21, 2019
P2, N=620, Completed, Sponsor: Richard Crosby
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2016 | Trial primary completion date: Aug 2018 --> May 2016 Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017
- | Trial completion, IO biomarker: MicroVIH: Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection (clinicaltrials.gov) - Feb 11, 2019
P1/2, N=45, Completed, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017 Active, not recruiting --> Completed
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Feb 11, 2019
P=N/A, N=403, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Stamaril (yellow fever vaccine) / Sanofi
Trial completion, Trial completion date, Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Jan 18, 2019
P3, N=71, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Dec 2017 | Trial primary completion date: Nov 2017 --> Feb 2017
- | Phase classification: HAPI: Healthy Activities for Prize Incentives (clinicaltrials.gov) - Dec 26, 2018
P=N/A, N=75, Completed, Sponsor: UConn Health
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Dec 2017 | Trial primary completion date: Nov 2017 --> Feb 2017 Phase classification: P1 --> P=N/A
- | Trial completion: PHAEDRA: An Observational Study of People Who Have Recently Been Infected With HIV (clinicaltrials.gov) - Nov 28, 2018
P=N/A, N=500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P1 --> P=N/A Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Enrollment change, Trial withdrawal: HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) - Nov 20, 2018
P1, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=13 --> 0 | Recruiting --> Withdrawn
- | Eyevinal (ibudilast) / MediciNova
Trial completion, Trial completion date: IBUD ph II: Trial of Ibudilast for Methamphetamine Dependence (clinicaltrials.gov) - Nov 15, 2018
P2, N=140, Completed, Sponsor: University of California, Los Angeles
N=13 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017
- | Trial completion: Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort (clinicaltrials.gov) - Nov 9, 2018
P=N/A, N=254, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017 Active, not recruiting --> Completed
- | Trial completion, Phase classification, Adherence: Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX (clinicaltrials.gov) - Nov 8, 2018
P2, N=200, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P3 --> P2
- | Trial completion: Improving Provider Counseling Interventions in HIV Practice (clinicaltrials.gov) - Oct 18, 2018
P=N/A, N=470, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | Phase classification: P3 --> P2 Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Enrollment change, Trial termination: RALBAT: Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (clinicaltrials.gov) - Oct 17, 2018
P4, N=4, Terminated, Sponsor: Giovanni Di Perri
Active, not recruiting --> Completed N=66 --> 4 | Recruiting --> Terminated; Low enrollment
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: PrEP-India: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India (clinicaltrials.gov) - Oct 11, 2018
P1, N=1325, Completed, Sponsor: University of Manitoba
N=66 --> 4 | Recruiting --> Terminated; Low enrollment Active, not recruiting --> Completed
- | Trial completion, Adherence: SPARK: Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=438, Completed, Sponsor: Hunter College of City University of New York
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Asha II: Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children (clinicaltrials.gov) - Oct 9, 2018
P=N/A, N=600, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: TLCIDU Kenya: Testing and Linkage to Care for Injecting Drug Users in Kenya (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=9449, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Apr 2016
- | rosuvastatin / Generic mfg.
Trial completion, Enrollment change: The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients (clinicaltrials.gov) - Oct 5, 2018
P4, N=35, Completed, Sponsor: Ottawa Heart Institute Research Corporation
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Apr 2016 Recruiting --> Completed | N=82 --> 35
- Selzentry (maraviroc) / ViiV Healthcare
Phase classification: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India (clinicaltrials.gov) - Sep 27, 2018
P=N/A, N=0, No Longer Available, Sponsor: ViiV Healthcare
Recruiting --> Completed | N=82 --> 35 Phase classification: P3 --> P=N/A
- | Trial primary completion date: Lactoferrin Treatment in HIV Patients (clinicaltrials.gov) - Sep 18, 2018
P2, N=55, Completed, Sponsor: Jason Baker
Phase classification: P3 --> P=N/A Trial primary completion date: Dec 2016 --> Jul 2017
- Aptivus (tipranavir) / Boehringer Ingelheim
Enrollment change: Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort (clinicaltrials.gov) - Aug 31, 2018
P=N/A, N=0, Withdrawn, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2016 --> Jul 2017 N=150 --> 0
- | abacavir/lamivudine/zidovudine / Generic mfg.
Phase classification: Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults (clinicaltrials.gov) - Aug 27, 2018
P4, N=152, Completed, Sponsor: GlaxoSmithKline
N=150 --> 0 Phase classification: P1 --> P4
- | Trial completion: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=205, Completed, Sponsor: FHI 360
Phase classification: P1 --> P4 Active, not recruiting --> Completed
- | mupirocin / Generic mfg.
Trial completion: Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=550, Completed, Sponsor: Uniformed Services University of the Health Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: The VMVN Study: Virological Monitoring in Viet Nam (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=650, Completed, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Enrollment change: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (clinicaltrials.gov) - Jul 26, 2018
P2, N=136, Completed, Sponsor: PATH
Active, not recruiting --> Completed N=104 --> 136
- | Trial completion: VIP-H1N1: Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (clinicaltrials.gov) - Jul 18, 2018
P2, N=450, Completed, Sponsor: Oswaldo Cruz Foundation
N=104 --> 136 Active, not recruiting --> Completed
- | Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial termination: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - Jul 11, 2018
P2/3, N=31, Terminated, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Completed --> Terminated
- | Trial completion date: Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=254, Active, not recruiting, Sponsor: Boston Medical Center
Completed --> Terminated Trial completion date: Apr 2018 --> Oct 2018
- | Trial completion date, Trial primary completion date: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Jun 18, 2018
P=N/A, N=205, Active, not recruiting, Sponsor: FHI 360
Trial completion date: Apr 2018 --> Oct 2018 Trial completion date: Apr 2018 --> Jun 2018 | Trial primary completion date: Apr 2018 --> Jun 2018
- ||| Isentress (raltegravir) / Merck (MSD)
Trial completion: Raltegravir in the Swiss HIV Cohort Study (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=200, Completed, Sponsor: University of Zurich
Trial completion date: Apr 2018 --> Jun 2018 | Trial primary completion date: Apr 2018 --> Jun 2018 Recruiting --> Completed
- | Enrollment change: Impact of Screening Patients With HIV for Kidney Disease (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=0, Withdrawn, Sponsor: University of Mississippi Medical Center
Recruiting --> Completed N=1400 --> 0
- || Enrollment change, Gene therapy: Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial (clinicaltrials.gov) - Jun 2, 2018
P2, N=68, Completed, Sponsor: Janssen-Cilag Pty Ltd
N=1400 --> 0 N=37 --> 68
- ||| Trial completion, Adherence: A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor (clinicaltrials.gov) - Apr 27, 2018
P=N/A, N=45, Completed, Sponsor: Montefiore Medical Center
N=37 --> 68 Active, not recruiting --> Completed
- | Trial completion: A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs) (clinicaltrials.gov) - Apr 27, 2018
P3, N=147, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: MAINTAIN: Micronutrients and Antioxidants in HIV Infection (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=171, Completed, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Completed Active, not recruiting --> Completed